Equitable Holdings Inc. bought a new stake in Boston Scientific Corporation (NYSE:BSX – Free Report) during the 2nd quarter, HoldingsChannel reports. The firm bought 29,331 shares of the medical equipment provider’s stock, valued at approximately $1,252,000.
A number of other institutional investors have also bought and sold shares of the company. Brighton Jones LLC grew its stake in Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after purchasing an additional 226 shares during the period. FWL Investment Management LLC acquired a new position in Boston Scientific in the second quarter valued at approximately $26,000. Main Street Financial Solutions LLC boosted its holdings in shares of Boston Scientific by 35.3% during the 2nd quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock worth $812,000 after buying an additional 1,971 shares in the last quarter. Ieq Capital LLC boosted its holdings in shares of Boston Scientific by 97.0% during the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock worth $13,275,000 after buying an additional 60,860 shares in the last quarter. Finally, HUB Investment Partners LLC grew its position in shares of Boston Scientific by 56.2% during the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock worth $763,000 after buying an additional 2,556 shares during the period. Institutional investors own 89.07% of the company’s stock.
Analysts Set New Price Targets
A number of research analysts recently issued reports on BSX shares. Raymond James Financial reiterated an “outperform” rating and set a $57.00 target price on shares of Boston Scientific in a research report on Thursday, July 30th. Royal Bank Of Canada reduced their price target on shares of Boston Scientific from $85.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, July 30th. Stifel Nicolaus set a $60.00 price target on shares of Boston Scientific in a research note on Wednesday, July 29th. Leerink Partners set a $60.00 price objective on shares of Boston Scientific in a report on Thursday, July 30th. Finally, Mizuho cut their price objective on shares of Boston Scientific from $90.00 to $70.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 15th. Twenty-four investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $71.62.
Boston Scientific Stock Performance
Shares of Boston Scientific stock opened at $46.82 on Friday. The company has a market cap of $67.85 billion, a PE ratio of 18.96, a price-to-earnings-growth ratio of 1.02 and a beta of 0.56. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $109.50. The business has a 50 day moving average price of $46.56 and a 200-day moving average price of $56.65. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.
Boston Scientific (NYSE:BSX – Get Free Report) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same quarter last year, the company earned $0.75 earnings per share. The company’s revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities analysts anticipate that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.
Boston Scientific declared that its board has authorized a stock buyback program on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s management believes its shares are undervalued.
Insider Buying and Selling at Boston Scientific
In other news, Director Edward J. Ludwig acquired 5,000 shares of the business’s stock in a transaction on Friday, July 31st. The shares were purchased at an average cost of $45.48 per share, with a total value of $227,400.00. Following the acquisition, the director directly owned 30,359 shares of the company’s stock, valued at $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David C. Habiger bought 2,100 shares of Boston Scientific stock in a transaction dated Wednesday, August 5th. The stock was purchased at an average price of $47.59 per share, with a total value of $99,939.00. Following the purchase, the director owned 17,160 shares in the company, valued at approximately $816,644.40. This represents a 13.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders have purchased 194,522 shares of company stock worth $9,385,210. Corporate insiders own 0.34% of the company’s stock.
Boston Scientific Profile
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
Read More
- Five stocks we like better than Boston Scientific
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
